Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.

Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, Nativi C, Richichi B, Scozzafava A, Carta F, Torre E, Supuran CT, Chiarugi P.

Cell Cycle. 2013 Jun 1;12(11):1791-801. doi: 10.4161/cc.24902. Epub 2013 May 8.

2.

Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay.

Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P, Chiarugi P.

Cancer Res. 2012 Oct 1;72(19):5130-40. doi: 10.1158/0008-5472.CAN-12-1949. Epub 2012 Jul 31.

3.

Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.

Lock FE, McDonald PC, Lou Y, Serrano I, Chafe SC, Ostlund C, Aparicio S, Winum JY, Supuran CT, Dedhar S.

Oncogene. 2013 Oct 31;32(44):5210-9. doi: 10.1038/onc.2012.550. Epub 2012 Dec 3.

PMID:
23208505
4.

Expression and activity of carbonic anhydrase IX is associated with metabolic dysfunction in MDA-MB-231 breast cancer cells.

Li Y, Wang H, Oosterwijk E, Tu C, Shiverick KT, Silverman DN, Frost SC.

Cancer Invest. 2009 Jul;27(6):613-23. doi: 10.1080/07357900802653464.

5.

Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.

Ambrosio MR, Di Serio C, Danza G, Rocca BJ, Ginori A, Prudovsky I, Marchionni N, Del Vecchio MT, Tarantini F.

Diagn Pathol. 2016 May 25;11(1):45. doi: 10.1186/s13000-016-0495-1.

6.

Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy.

McIntyre A, Patiar S, Wigfield S, Li JL, Ledaki I, Turley H, Leek R, Snell C, Gatter K, Sly WS, Vaughan-Jones RD, Swietach P, Harris AL.

Clin Cancer Res. 2012 Jun 1;18(11):3100-11. doi: 10.1158/1078-0432.CCR-11-1877. Epub 2012 Apr 12.

7.

Optimization of a novel peptide ligand targeting human carbonic anhydrase IX.

Rana S, Nissen F, Marr A, Markert A, Altmann A, Mier W, Debus J, Haberkorn U, Askoxylakis V.

PLoS One. 2012;7(5):e38279. doi: 10.1371/journal.pone.0038279. Epub 2012 May 31.

8.

Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis.

Yu SJ, Yoon JH, Lee JH, Myung SJ, Jang ES, Kwak MS, Cho EJ, Jang JJ, Kim YJ, Lee HS.

Acta Pharmacol Sin. 2011 Jul;32(7):912-20. doi: 10.1038/aps.2011.24. Epub 2011 Jun 13.

9.

Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH.

Svastová E, Hulíková A, Rafajová M, Zat'ovicová M, Gibadulinová A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, Pastoreková S.

FEBS Lett. 2004 Nov 19;577(3):439-45.

10.

Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion.

Robertson N, Potter C, Harris AL.

Cancer Res. 2004 Sep 1;64(17):6160-5.

11.

Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.

Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouysségur J.

Cancer Res. 2009 Jan 1;69(1):358-68. doi: 10.1158/0008-5472.CAN-08-2470.

12.

Targeting tumor-associated carbonic anhydrase IX in cancer therapy.

Thiry A, Dogné JM, Masereel B, Supuran CT.

Trends Pharmacol Sci. 2006 Nov;27(11):566-73. Epub 2006 Sep 25.

PMID:
16996620
13.

Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII.

Guler OO, De Simone G, Supuran CT.

Curr Med Chem. 2010;17(15):1516-26. Review.

PMID:
20166929
14.

Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.

Puccetti L, Fasolis G, Cecchi A, Winum JY, Gamberi A, Montero JL, Scozzafava A, Supuran CT.

Bioorg Med Chem Lett. 2005 May 2;15(9):2359-64.

PMID:
15837325
15.

Targeting carbonic anhydrase IX activity and expression.

Mahon BP, Pinard MA, McKenna R.

Molecules. 2015 Jan 30;20(2):2323-48. doi: 10.3390/molecules20022323. Review.

16.

Increased expression of carbonic anhydrase IX in oral submucous fibrosis and oral squamous cell carcinoma.

Yang JS, Chen MK, Yang SF, Chang YC, Su SC, Chiou HL, Chien MH, Lin CW.

Clin Chem Lab Med. 2014 Sep;52(9):1367-77. doi: 10.1515/cclm-2014-0129.

PMID:
24695043
17.

Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties.

Genis C, Sippel KH, Case N, Cao W, Avvaru BS, Tartaglia LJ, Govindasamy L, Tu C, Agbandje-McKenna M, Silverman DN, Rosser CJ, McKenna R.

Biochemistry. 2009 Feb 17;48(6):1322-31. doi: 10.1021/bi802035f.

18.

Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.

Tafreshi NK, Lloyd MC, Proemsey JB, Bui MM, Kim J, Gillies RJ, Morse DL.

Mol Imaging Biol. 2016 Apr;18(2):219-31. doi: 10.1007/s11307-015-0885-x.

19.

Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.

Cecchi A, Hulikova A, Pastorek J, Pastoreková S, Scozzafava A, Winum JY, Montero JL, Supuran CT.

J Med Chem. 2005 Jul 28;48(15):4834-41.

PMID:
16033263
20.

Carnosine inhibits carbonic anhydrase IX-mediated extracellular acidosis and suppresses growth of HeLa tumor xenografts.

Ditte Z, Ditte P, Labudova M, Simko V, Iuliano F, Zatovicova M, Csaderova L, Pastorekova S, Pastorek J.

BMC Cancer. 2014 May 22;14:358. doi: 10.1186/1471-2407-14-358.

Supplemental Content

Support Center